Upregulation of PD-1 Expression and High sPD-L1 Levels Associated with COVID-19 Severity
Autor: | Danielle Rosa Beserra, Ricardo Wesley Alberca, Anna Claudia Calvielli Castelo Branco, Luana de Mendonça Oliveira, Milena Mary de Souza Andrade, Sarah Cristina Gozzi-Silva, Franciane Mouradian Emidio Teixeira, Tatiana Mina Yendo, Alberto José da Silva Duarte, Maria Notomi Sato |
---|---|
Rok vydání: | 2022 |
Předmět: | |
Zdroj: | Journal of Immunology Research. 2022:1-9 |
ISSN: | 2314-7156 2314-8861 |
DOI: | 10.1155/2022/9764002 |
Popis: | COVID-19 has several mechanisms that can lead to lymphocyte depletion/exhaustion. The checkpoint inhibitor molecule programmed death protein 1 (PD-1) and its programmed death-ligand 1 (PDL-1) play an important role in inhibiting cellular activity as well as the depletion of these cells. In this study, we evaluated PD-1 expression in TCD4+, TCD8+, and CD19+ lymphocytes from SARS-CoV-2-infected patients. A decreased frequency of total lymphocytes and an increased PD-1 expression in TCD4+ and CD19+ lymphocytes were verified in severe/critical COVID-19 patients. In addition, we found a decreased frequency of total monocytes with an increased PD-1 expression on CD14+ monocytes in severe/critical patients in association with the time of infection. Moreover, we observed an increase in sPD-L1 circulant levels associated with the severity of the disease. Overall, these data indicate an important role of the PD-1/PDL-1 axis in COVID-19 and may provide a severity-associated biomarker and therapeutic target during SARS-CoV-2 infection. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |